## AKT BOOSTERS 2023/24 - Start time: 1330

6 <sup>th</sup> September	Acne management Andy Moriarty	<b>Drug monitoring</b> Dayo	
20 <sup>th</sup> September	Notification of death requirements Adewumi Akinwande	Possible emergency presentations Rasheed Odunusi	<mark>Social media</mark>
4 <sup>th</sup> October	Medically unexplained	<b>Child development</b>	<b>Diagnosis of cancer</b>
	symptoms	Hameed Quadri	Sheraj Fernandez
1 <sup>st</sup> November	SEs of drugs used for long term	Antimicrobial	Long term conditions in
	conditions	stewardship	children
	Muhammad Ejaz	Gireesha Verma	Shona Kohlhardt
20 <sup>th</sup> December	Contraception with teratogenic drugs Ben Tyler	Management of asthma Said Kareem	<b>Eyelid conditions</b> Lauren Wallis
10 <sup>th</sup> January	Access to medical records/privacy issues KK Sunn	Causes of erectile dysfunction Mayuran Panchalingam	<b>DMARD side effects</b> Talha Syed
17 <sup>th</sup> January	<b>Diagnosis of pregnancy</b>	ECG interpretation	<b>GI symptoms</b>
	Binumol Abraham	Sam	Ahmed El Khouly
7 <sup>th</sup> February	End of life prescribing Muzammil	Management of hypertension Chioma	<b>Emergency</b> contraception Phyo Thu
21 <sup>st</sup> February	Management of long-term GI	Occupational vaccine	Common genetic
	conditions	requirements	conditions
	Atif Ali	Engy Abdelrahim	Shereen Abdo
20 <sup>th</sup> March	Prostate cancer Mohamed Ahmed	Care of transgender people Adefunke Adetula	Hearing loss Sarah Ghanem
17 <sup>th</sup> April	Management of mental health	<b>Treating menopausal</b>	<b>Red flag symptoms in</b>
	problems	symptoms	<b>neurology</b>
	Priya Patel	Wesam Farah	Alla Abukashim
1 <sup>st</sup> May	<b>Consent and capacity</b>	FBC interpretation	Insulin regimens
	Kate Allen	Terry Debo	Joseph Olupona
5 <sup>th</sup> June	Management of irregular	Common endocrine	Common childhood
	periods	conditions	infections
	Alaa Kaooh	Sanaa Malik	Heba A
19 <sup>th</sup> June	<b>Genital skin conditions</b>	<b>Domestic abuse</b>	Common oral problem
	Akinwale Bodunwa	Sabiha Alam	Mustafa Ibraheem

Oral antidiabetic agents.

Common rheumatological problems (Dx).

Interpretation of spirometry

Risk communication

Drug dose calculation

Developmental assessment/screening.